Goodrx Holdings, INC Form 4 insider transactions

Christopher McGinnis, CFO of GoodRx Holdings, reports the acquisition of restricted stock units and stock options in Class A Common Stock.

Wendy Lynn Barnes, a Director and Officer (Chief Executive Officer and President) of GoodRx Holdings, Inc., reported the acquisition of stock options and restricted stock units.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., reported the acquisition and disposal of Class A Common Stock and Restricted Stock Units on February 8, 2025.

Director Scott Wagner reports the acquisition of Class A Common Stock and Deferred Stock Units in GoodRx Holdings, Inc.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

GoodRx's Chief Financial Officer, Karsten Voermann, engaged in stock transactions involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.

GoodRx director Douglas Hirsch reported the acquisition of deferred stock units and indirect holdings through grantor retained annuity trusts.

Director Ronald E Bruehlman of GoodRx Holdings, Inc. acquired 10,653 deferred stock units on January 1, 2025, which will vest monthly starting January 31, 2025.

GoodRx director Kelly J. Kennedy acquired 23,150 shares of Class A common stock through the vesting of restricted stock units.

GoodRx Holdings' Interim CEO, Scott Wagner, executed transactions involving Class A common stock and restricted stock units, as detailed in a recent SEC Form 4 filing.

GoodRx's Chief Financial Officer, Karsten Voermann, engaged in stock transactions involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reported the acquisition and disposal of Class A common stock and restricted stock units on December 8, 2024.

GoodRx director Ronald E. Bruehlman acquired shares through deferred stock units, as detailed in a recent SEC Form 4 filing.

GoodRx Holdings' Interim CEO, Scott Wagner, reports the acquisition and disposal of Class A common stock and restricted stock units.

GoodRx Holdings' Chief Accounting Officer, Romin Nabiey, executed transactions involving Class A common stock and restricted stock units, as detailed in a recent SEC Form 4 filing.

Director Douglas Joseph Hirsch reports transactions involving GoodRx Holdings Class A Common Stock, including acquisitions of deferred and restricted stock units, as well as holdings through grantor retained annuity trusts.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on October 15, 2024.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on October 8, 2024.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Spectrum Equity VII, L.P. and affiliated funds converted Class B Common Stock to Class A Common Stock of GoodRx Holdings, Inc. and distributed shares, with some shares subsequently sold.

Douglas Joseph Hirsch, Chief Mission Officer at GoodRx Holdings, reports the vesting and conversion of restricted stock units and subsequent transactions involving Class A and Class B common stock.

Trevor Bezdek, Chairman of GoodRx Holdings, reports the vesting and conversion of restricted stock units and Class B common stock into Class A common stock, along with a disposition of shares to cover tax obligations.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc., sold 79,000 shares of Class A Common Stock on August 12, 2024, at a weighted average price of $6.7674.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on August 8, 2024.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Agnes Rey-Giraud, a director of GoodRx Holdings, acquired 2,464 shares of Class A Common Stock on July 8, 2024.

Director Kelly J. Kennedy acquired 2,464 shares of GoodRx Holdings, Inc. Class A common stock on July 8, 2024, and holds 30,862 shares.